All News
Bimekizumab is Coming… in Third Place
Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA.
Read ArticlePulmonary Manifestations of Rheumatic Disease in Asymptomatic Patients
In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggest
Read ArticleEric Dein ( View Tweet)
Eric Dein ( View Tweet)
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)